freeline
appoints
mark
baldry
chief
commercial
officer
london
globe
newswire
freeline
therapeutics
holdings
plc
nasdaq
frln
company
freeline
fully
integrated
next
generation
systemic
gene
therapy
company
ambition
transforming
lives
patients
suffering
inherited
systemic
debilitating
diseases
announced
mark
baldry
mba
today
appointed
company
new
chief
commercial
officer
effective
today
date
mark
experienced
commercial
leader
track
record
positions
increasing
responsibility
leading
biopharmaceutical
companies
marketing
sales
public
affairs
roles
across
europe
canada
us
predominately
worked
across
rare
specialty
disease
areas
championed
multiple
commercial
launches
mark
appointment
chief
commercial
officer
reflects
strong
background
commercialisation
products
rare
diseases
including
fabry
gaucher
disease
said
theresa
heggie
chief
executive
officer
freeline
transformative
year
freeline
encouraging
clinical
progress
across
programmes
strengthened
management
team
mark
great
addition
potential
gene
therapy
change
patients
lives
never
greater
look
forward
working
mark
continue
develop
pipeline
innovative
product
candidates
commercialisation
meet
needs
mark
joins
freeline
wave
life
sciences
served
chief
commercial
officer
prior
senior
vice
president
global
marketing
commercial
operations
amicus
therapeutics
roles
responsible
building
global
commercial
strategies
support
launches
innovative
medicines
orphan
diseases
including
first
oral
chaperone
therapy
treatment
fabry
disease
prior
mark
held
multiple
leadership
positions
biogen
including
vice
president
public
affairs
vice
president
new
product
commercialisation
also
held
leadership
roles
human
genetic
therapies
division
shire
including
head
global
strategic
marketing
head
marketing
market
access
public
affairs
europe
middle
east
africa
mark
earned
mba
concordia
university
canada
holds
bsc
genetics
york
university
uk
freeline
freeline
biotechnology
company
focused
gene
therapy
targeting
liver
vision
create
better
lives
people
suffering
chronic
systemic
diseases
using
potential
gene
therapy
treatment
provide
potential
functional
cure
freeline
headquartered
uk
operations
germany
us
statements
press
release
contains
statements
constitute
forward
looking
statements
term
defined
united
states
private
securities
litigation
reform
act
including
statements
express
company
opinions
expectations
beliefs
plans
objectives
assumptions
projections
regarding
future
events
future
results
contrast
statements
reflect
historical
facts
examples
include
discussion
company
strategies
financing
plans
clinical
trial
plans
cases
identify
statements
terminology
anticipate
intend
believe
estimate
plan
seek
project
expect
may
would
could
negative
terms
similar
expressions
forward
looking
statements
based
management
current
beliefs
assumptions
information
currently
available
company
place
undue
reliance
statements
statements
subject
many
risks
uncertainties
including
company
recurring
losses
operations
development
company
product
candidates
including
statements
regarding
timing
initiation
completion
outcome
clinical
studies
trials
related
preparatory
work
company
ability
design
implement
successful
clinical
trials
product
candidates
potential
pandemic
epidemic
outbreak
infectious
diseases
eu
including
pandemic
disrupt
company
clinical
trial
pipeline
company
failure
demonstrate
safety
efficacy
product
candidates
fact
results
obtained
earlier
stage
clinical
testing
may
indicative
results
future
clinical
trials
company
ability
enroll
patients
clinical
trials
product
candidates
possibility
one
company
product
candidates
may
cause
serious
adverse
undesirable
unacceptable
side
effects
properties
could
delay
prevent
regulatory
approval
limit
commercial
potential
company
ability
obtain
maintain
regulatory
approval
product
candidates
company
limited
manufacturing
experience
could
result
delays
development
commercialization
product
candidates
company
ability
identify
discover
additional
product
candidates
failure
capitalize
programmes
product
candidates
risks
uncertainties
may
cause
statements
inaccurate
readers
cautioned
place
undue
reliance
statements
many
risks
outside
company
control
could
cause
actual
results
differ
materially
thought
would
occur
statements
included
press
release
made
date
hereof
company
undertake
specifically
declines
obligation
update
statements
publicly
announce
results
revisions
statements
reflect
future
events
developments
except
required
law
information
please
reference
company
reports
documents
filed
securities
exchange
commission
may
get
documents
visiting
edgar
sec
website
information
jw
communications
julia
wilson
juliawilsonuk
